After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
1don MSN
Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...
1d
MedPage Today on MSNPatients Struggle With Lack of Consistent Coverage for New Weight-Loss DrugsCoverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
5don MSNOpinion
More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
People with a high body weight living in England can now access subsidized weight-loss drugs to treat their obesity. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results